Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/4965—Non-condensed pyrazines
  • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
  • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
  • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/22—Anxiolytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/24—Antidepressants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
  • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/04—Anorexiants; Antiobesity agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/06—Antihyperlipidemics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Definitions

• the present invention relates to the use of 1-[4-(5-cyanoindol-3-yl)butyf]-4- (2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof, for the manufacture of a medicament for the treatment of subtype anxiety disorders.
• ⁇ - methyldopa ⁇ - methyldopa
• prophylaxis and therapy of cerebral disorders e.g. migraine
• cerebral disorders e.g. migraine
• endocrinology and gynecology e.g. for the treatment of acromegaly, hypogonadism, secondary amenorrhea, premenstrual syndrome or undesired puerperal lactation.
• sleep disorders including dyssomnias and narcolepsy.
• the invention had the object of providing novel uses for 1-[4-(5-cyanoindol- 3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and its physiologically acceptable salts having significantly better pharmacological properties than compounds of the prior art.
• 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl- benzofuran-5-yl)-piperazine also has activity against sub-type anxiety disorders chosen from the sub-types panic disorder with and/or without agoraphobia, agoraphobia, obsessive-compulsive spectrum disorders, social phobia, specific phobia including neophobia, posttraumatic stress disorder, acute stress indication or generalized-anxiety disorder.
• the present invention relates to the use of 1-[4-(5-cyanoindol- 3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof, for the manufacture of a medicament for the treatment of sub-type anxiety disorders chosen from the sub-types panic disorder with or without agoraphobia, agoraphobia, obsessive-compulsive spectrum disorders including obsessive compulsive disorders, social phobia, specific phobia including neophobia, posttraumatic stress disorder, acute stress indication and/or generalized-anxiety disorder.
• sub-type anxiety disorders chosen from the sub-types panic disorder with or without agoraphobia, agoraphobia, obsessive-compulsive spectrum disorders including obsessive compulsive disorders, social phobia, specific phobia including neophobia, posttraumatic stress disorder, acute stress indication and/or generalized-anxiety disorder.
• 5-HT reuptake inhibitors such as fluoxetine (L Solyom, C. Solyom, B. Ledwidge, Can. J. Psychiatry, 1991 , 36: 378-380) or 5-HT 1A receptor agonists such as geprione (J.C. Pecknold, L. Luthe, M.H. Scott- Fleury, S. Jenkins, J. Clin. Psychopharmacology, 1993, 13: 145-149) are clinically effective in panic disorders. It has been found that a combined selective 5-HT reuptake inhibitor and 5-HT 1A receptor agonist which includes both mechanisms leads to an advantage in clinical practice.
• a typical model for panic disorder is the Mouse Defense Test Battery according to G. Griebel, D.C. Blanchard, R.J. Blanchard, Prog.
• the mouse defence battery test consists of an oval runway of 2 m straight segments joint by two 0.4 m curved segments separated by a median wall. A mouse is placed in the runway for a 3 min familiarization period. Then, a hand-held anaesthetized rat is introduced into the runway and brought up to the mouse. Approach is terminated when contact with the mouse was made or the mouse runs away from the approaching rat. If the subject runs away, avoidance distance and the number of avoidances after five approaches are recorded. Immediately after these approaches, the rat chases the mouse for a distance of 15 m, and flight speed is recorded.
• a typical model for Agoraphobia is named Elevated Plus Maze according to S. Pellow, P. Chopin, S.E. File, M. Briley, J. Neurosci. Meth., 1985, 14: 145-167.
• the apparatus consists of an X-shaped platform elevated from the floor, with two "open” unprotected arms and two "closed” protected arms, with animals having free access to both arms.
• the rat or mouse is placed in the centre of the arms, and the number of entires made and the time spent on the open arms is measured in a 3 min test period. Normal animals have very low basal levels, i.e. avoid entering the open arms and stay only a for a very brief period on open arms.
• 5-HT reuptake inhibitors such as paroxetine (A.K. Cardogan, I.K. Wright, I. Combs, CA. Marsden, D.A. Kendall, I. Tulloch, Neurosci. Lett. 42: S8) or 5-HT 1A receptor agonists such as geprione (V. Motta, S. Maisonnette; S. Morato; P. Castrechini; M.L Brandao, Psychopharmacotogy, 1992; 107: 135-139) or 8-OH-DPAT (8-hydroxy- dipropylaminotetralin) (N. Collinson, G.R.
• Obsessive Compulsive Disorders are characterized by unwanted intrusive, recurring thoughts, images, or actions which generate an irrational dread (obsession) of germs, dirt, contamination, apprehension of acting on violent or aggressive impulses, feeling overly responsible for the safety of others, e.g. unreasonable dread of having run over someone with a car, abhorrent religious (blasphemous) and sexual thoughts, inordinate concern with order, arrangement, or symmetry, inability to discard useless or worn out possessions.
• OCDs Obsessive Compulsive Disorders
• Obsessive Compulsive Spectrum Disorders share common features with OCDs including overlapping symptom profiles, demographics, family history, comorbidity, clinical course and response to anti-obsessional treatment.
• OCSDs include e.g. somatoform disorders (e.g. body dysmorphobia, hypochondriasis), tic disorders (e.g. Gilles de la Tourette's syndrome), impulsive personality disorders (e.g. antisocial personality disorder), impulse control disorders (e.g. trichotillomania, kleptomania, pyromania, pathological gambling, sexual compulsions such as exhibitionism, voyeurism, fetishism), schizo-obsessive disorders(e.g. obsessional schizophrenia, schizotypic OCD, delusional OCD), dissociative disorders (e.g. autism, torticolis, Sydenham's Chorea, Asperger's syndrome) [for review e.g. E. Hollander and C. Wong, J. Clin. Psychiatry 1995, 56 (suppl. 4): 3 or McElroy et al., J. Clin. Psychiatry 1994, 55 (suppl. 10): 33].
• a typical model for OCSD including OCD is the Marble Burying Test according to Y. Ichimaru, T. Egawa, A. Sawa, Jpn. J. Pharmacol. 1995, 68: 65-70.
• the apparatus consists of an open cubic box with 25 clean glass marbles evenly spaced on sawdust. Individual mice are placed in the test box, and the number of glass marbles left uncovered after 20 minutes are counted.
• a dose of 3 mg/kg of 1-[4-(5- cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride nearly completely (92%) inhibits marble burying; equieffective doses of conventional serotonin reuptake inhibitors are e.g. 20 mg/kg for fluvoxamine or 17 mg/kg for fluoxetine and an equieffective dose of the 5-HT 1A agonist ipsapirone is 10 mg/kg.
• 5-HT reuptake inhibitors or 5-HT 1A receptor agonists inhibit marble burying, e.g. fluvoxamine, citalopram or 8-OH-DAPT, gepirone (K. Njung'e, S.L Handley, Br. J. Pharmacol., 104: 105-112; ). So-far the selective serotonine reuptake inhibitors (SSRIs) are chosen for the treatment of OCSD (W.K. Goodman, L.H. Price, P.L Delgado, Arch. Gen. Psychiatry 1990, 47: 577-585). It has been found that a combined selective 5-HT reuptake inhibitor and 5-HT 1A receptor agonist has an increased activity and a faster onset of action.
• SSRIs selective serotonine reuptake inhibitors
• a model for social phobia is the Social Interaction Test according to S. File, J.R.G Hyde, J. Pharm. Pharmacol. 1977, 29: 735-738.
• a model for specific phobia is the Shock-Probe Test according to D. Treit, M.A. Fundytus, Pharmacol. Biochem. Behav. 1988, 30: 1071-1075. Individual rats are habituated for 30 min each of 4 days to an open box filled with sawdust. On the test day, a continuously electrified probe is inserted 2 cm above the ground. The number of contacts with the probe is counted and the attemps to cover the probe with sawdust are recorded.
• mice deprived from food for 18 h are given access to unfamiliar food in a novel environment [P. Soubrie et al., Psychopharmacologica, 1975, 45: 203-210].
• Animal models of anxiety associated with posttraumatic stress in rats utilize the long-lasting behavioural changes induced by exposure to a native stressor.
• the therapeutic effects of a compound effective for the acute treatment of anxiety associated with posttraumatic stress are modelled by administration of the compound after exposure to the stressor.
• the therapeutic effects of a compound effective for the prophylactic treatment of anxiety associated with posttraumatic stress are modelled by administration of the compound before exposure to the stressor.
• the following is most validated [R.E. Adamec and T. Shallow, Physiology Behavior, 1993, 54: 101-109; R.E. Adamec et al., Behav. Neurosci. 1997, 111 : 435-449].
• a rat In general, a rat is exposed to a cat for five minutes, and seven days later the rat can be tested in a battery of tests, i.e. the hole board test, the elevated plus maze and the acoustic startle test.
• the hole board consists of a box (60 cm x 60 cm) with four evenly spaced holes; the number of poking its head into a hole is counted for 5 minutes.
• the elevated plus maze consists of an X- shaped platform elevated from the floor, with two "open” unprotected arms and two "closed” protected arms, with rats having free access to both arms.
• the rat is placed in the centre of the arms, and the frequency of attempts to enter an open arm (risk assessment) as well as the time spent on the open and closed arms are measured.
• the rat In the acoustic startle test, the rat is placed in a plexiglass cylinder, and a series of 20 white noise bursts of 120 dB out of a background noise of 60 dB is applied, and the latency to and the peak startle amplitude are measured.
• rats exposed to the a stressor like a cat show a reduced number of head dips into the holes, have a lower risk assessment and spend less time on the open arms, and the startle response is increased.
• 1-[4-(5-cyanoindol-3-yl)butyi]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or one of its physiologically acceptable salts, in particular 1-[4-(5- cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride, are effective in the models for anxiety associated with posttraumatic stress when given after (acute treatment) and before (prophylactic treatment) the cat stressor.
• a typical model for generalized anxiety disorders is the Light-Dark Choise Test (Passive Avoidance Test) according to J.N. Crawly, Pharmacol. Biochem Behav. 1981 , 15: 695-699.
• the light-dark choise apparatus consists of two connected boxes with one box darkened and the other one highly illuminated. A mouse is placed in one box, and the time spent in lit box and the number of transitions between boxes are measured over a period of 5 min. Normal mice only have low numbers of entries to the lit compartment and spent most time in the dark compartment.
• an oral dose of 10mg/kg of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl- benzofuran-5-yl)-piperazine hydrochloride increased the number of transitions by 73% and time spent in lit compartment by 31 %.
• 5-HT reuptake inhibitors imipramine (R. Young, D.N. Johnson, Pharmacol. Biochem. Behav., 1991 , 40: 739-743), or the 5-HT 1A receptor agonists e.g. 8-OH-DPAT and ipsapirone (B. Costall; A.M. Domeney, A.J. Farre; M.E. Kelly; L. Martinez; R.J. Naylor, J. Pharmacol. Exp. Ther., 1992, 262: 90-98) that they increase time spent in illuminated compartment and number of transitions between compartments. It has been found that a combined selective 5-HT reuptake inhibitor and 5-HT 1A receptor which includes both mechanisms leads to therapeutic advantages.
• a preferred salt of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl- benzofuran-5-yl)-piperazine is 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2- carbamoyt-benzofuran-5-yl)-piperazine hydrochloride. Therefore the invention relates to the use for the manufacture of a medicament for the treatment of sub-type anxiety disorders in which the pharmacologically acceptable salt is 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2- carbamoyl-benzofuran-5-yl)-piperazine hydrochloride.
• the invention relates to the use of a pharmaceutical composition containing at least one compound of 1-[4-(5-cyanoindol-3- yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and/or one of its biocompatible salts together with at least one solid, liquid or semiliquid excipient or adjunct for the treatment of sub-type anxiety disorders chosen from the sub-types panic disorder with and/or without agoraphobia, agoraphobia, obsessive-compulsive spectrum disorders, social phobia, specific phobia including neophobia, posttraumatic stress disorder, acute stress indication or generalized-anxiety disorder.
• sub-type anxiety disorders chosen from the sub-types panic disorder with and/or without agoraphobia, agoraphobia, obsessive-compulsive spectrum disorders, social phobia, specific phobia including neophobia, posttraumatic stress disorder, acute stress indication or generalized-anxiety disorder.
• the invention provides a pharmaceutical preparation for the treatment of such sub-type anxiety disorders characterized in that it contains at least 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yi)-piperazine or one of its pharmaceutically acceptable salts.
• the compounds, 1 -[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran- 5-yl)-piperazine and its pharmaceutically acceptable salts, according to the invention are preferably administered in analogy to other known commercially available preparations for the treatment of sub-type anxiety disorders (e.g. fluoxetine, fluvoxamine).
• a unit dose will generally contain from 0.1 to 1000 mg, preferably between approximately 0.1 and 500 mg, in particular 5, 10, 20, 30, 40, 50, 100, 150, 200, 250 and 300 mg.
• the composition may be administered once or more times a day for example 2, 3 or 4 times daily.
• the daily dose is preferably between approximately 0.01 and 50 mg/kg of body weight.
• the specific dose for each patient depends on all sorts of factors, for example on the activity of the specific compound employed, on the age, body weight, general state of health, sex, on the diet, on the time and route of administration, on the excretion rate, pharmaceutical substance combination and severity of the particular disorder to which the therapy relates.
• Oral administration is preferred, but also peroral routes of administration (e.g. intraveneous or transdermal) can be utilized.
• peroral routes of administration e.g. intraveneous or transdermal
• 1-[4-(5-cyanoindol-3- yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine also has activity against bipolar disorders and/or mania.
• a typical animal model of mania/bipolar disorders is the hyperactivity induced by a mixture of dexamphetamine and chlordiazepoxide according to A.L. Vale and F. Ratcliffe, Psychopharmacology, 1987; 91 : 352-355. and B.J. Cao and N.A. Peng, Eur. J. Pharmacol., 1993; 237: 177-181.
• the dexamphetamine-chlordiazepoxide mixture induces strong hyperactivity in mice or rats.
• the present invention relates to the use of 1-[4-(5-cyanoindol- 3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof, for the manufacture of a medicament for the treatment of bipolar disorders and/or mania.
• a typical clinical study for bipolar disorders and/or mania is described in the following. Twenty ( 20 ) male or female patients aged 18-65 years suffering from an acute hypomanic episode as part of a Bipolar II Disorder as diagnosed by DSM-IV will be treated for a 3 week period with either 1-[4-(5-cyanoindol-3- yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or one of its physiologically acceptable salts or lithium in a double-blind fashion. Clinical improvement will be assessed by means of the Mania sub-scale of the SADS-C according to R.R. Lewine et al., Schizophr. Bull.
• the invention relates furthermore to the use for the manufacture of a medicament for the treatment of bipolar disorders and/or mania in which the pharmacologically acceptable salt is 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2- carbamoyl-benzofuran-5-yl)-piperazine hydrochloride.
• the invention relates to the use of a pharmaceutical composition containing at least one compound of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2- carbamoyl-benzofuran-5-yl)-piperazine and/or one of its biocompatible salts together with at least one solid, liquid or semiliquid excipient or adjunct for the treatment of bipolar disorders and/or mania.
• the invention provides a pharmaceutical preparation for the treatment of bipolar disorders and/or mania characterized in that it contains at least 1- [4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or one of its pharmaceutically acceptable salts.
• the compounds according to the invention are preferably administered in analogy to other known commercially available preparations for the treatment of bipolar disorders and/or mania (e.g. fluoxetine, fluvoxamine), preferably in doses of between approximately 0.1 and 500 mg, in particular between 5 and 300 mg per dose unit.
• the daily dose is preferably between approximately 0.01 and 10 mg/kg of body weight.
• the specific dose for each patient depends on all sorts of factors, for example on the activity of the specific compound employed, on the age, body weight, general state of health, sex, on the diet, on the time and route of administration, on the excretion rate, pharmaceutical substance combination and severity of the particular disorder to which the therapy relates.
• Oral administration is preferred, but also peroral routes of administration (e.g. intraveneous or transdermal) can be utilized.
• the present invention relates to the use of 1-[4-(5-cyanoindol- 3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof, for the manufacture of a medicament for the treatment of dementia.
• Typical models for dementia, Alzheimer's disease and multi-infarct are the Passive Avoidance test in rats [S.D. Glick and B. Zimmerberg, Behav. Biol.,
• the apparatus is a runway separated from a dark compartment by a small door.
• the amnestic drug scopolamine is administerd before the animal is submitted to an aquisition trial: the rat is placed on the entry of the runway opposite to the dark compartment, the latency to enter the dark compartment is recorded, and once the rat has entered the dark compartment, the door is closed and a foot schock is administered via the gridfloor.
• a retention trial is performed 48 h later identical to the aquisition trial (without scopolamine) and the latency to enter the dark compartment recorded again.
• the Morris Water Maze consists of a circular water tank (150 cm in diameter) filled with water with an escape platform (15 cm in diameter) 18 cm from the periphery beneath the surface of the water. The water is made opaque rendering the platform invisible. Rats placed in the tank swim around and find the hidden platform accidently after a certain time (latency), and the latency to find the platform is taken as measure. When given further training session to find the platform, rats show reduced latencies from day to day, i.e. remember (learn) the location of the platform. But compared to young rats, aged rats perform less well in learning over days reflecting impaired learning capacity. Drugs effective for dementia and particularly Alsheimers disease improve the learning capacity of aged rats.
• 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride is adminstered to old rats at oral doses of 1 and 3 mg/kg every day.
• the latencies to find the platform in the first attempt are 77 sec (1 mg/kg) and 73 sec (3 mg/kg) not differing from vehicle treated young rats (76 sec) whereas untreated old rats needed 95 sec to find the platform.
• the invention relates furthermore to the use for the manufacture of a medicament for the treatment of dementia in which the pharmacologically acceptable salt is 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran- 5-yl)-piperazine hydrochloride.
• the invention relates to the use of a pharmaceutical composition containing at least one compound of 1-[4-(5-cyanoindol-3- yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and/or one of its biocompatible salts together with at least one solid, liquid or semiliquid excipient or adjunct for the treatment of dementia.
• the invention provides a pharmaceutical preparation for the treatment of dementia characterized in that it contains at least 1-[4-(5-cyanoindol-3- yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or one of its pharmaceutically acceptable salts.
• the compounds according to the invention are preferably administered in analogy to other known commercially available preparations for the treatment of dementia including Alzheimer's disease and multi-infarct (e.g. fluoxetine, fluvoxamine), preferably in doses of between approximately 0.1 and 500 mg, in particular between 5 and 300 mg per dose unit.
• the daily dose is preferably between approximately 0.01 and 50 mg/kg of body weight.
• the specific dose for each patient depends on all sorts of factors, for example on the activity of the specific compound employed, on the age, body weight, general state of health, sex, on the diet, on the time and route of administration, on the excretion rate, pharmaceutical substance combination and severity of the particular disorder to which the therapy relates.
• Oral administration is preferred, but also peroral routes of administration (e.g. intraveneous or transdermal) can be utilized.
• the present invention relates to the use of 1-[4-(5-cyanoindol- 3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof, for the manufacture of a medicament for the treatment of substance-related disorders.
• Substance-related disorders include substance dependence with or without its withdrawal symptoms, substance-induced mood disorder and substance-induced anxiety disorder.
• “Substance” is herein defined as alcohol, amphetamine, cannabis, cocaine, hallucinogen, opoid, phencyclidine, nicotine and/or tobacco for substance dependence.
• “Substance” is defined as alcohol, amphetamine, cocaine, hallucinogen, inhalant, opoid and/or phencyclidine for substance-induced mood disorder and for substance-induced anxiety disorder.
• 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl- benzofuran-5-yl)-piperazine is preferably active against alcohol- dependance and/or against nicotine (tobacco) withdrawal symptoms.
• Nicotine withdrawal symptoms include restlessness, irritability, drowsiness, increasingly frequent wakings from sleep, impatience, confusion, impaired concentration, carbohydrate craving and weight gain, impaired reaction time and a craving for tobacco.
• the invention relates furthermore to the use for the manufacture of a medicament for the treatment of substance-related disorders in which the pharmacologically acceptable salt is 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2- carbamoyl-benzofuran-5-yl)-piperazine hydrochloride.
• a typical animal model is the drug discrimination procedure in rats using cocaine as the stimulus cue (e.g. D.M. Wood and M.W. Emmett-Oglesby, J. Pharmacol. Exp. Ther., 1986; 237: 120-125; D. Huang and M.C. Wilson, Pharmacol. Biochem. Behav., 1986; 24: 205-210; J.M. Witkin at al., J. Pharmacol. Exp. Ther., 1991 ; 257: 706-713).
• Rats are trained to discriminate 10 mg/kg cocaine from saline in a two-lever discrimination procedure.
• Compounds which substitute for cocaine produce a dose- dependent increase in cocaine-appropriate responding, i.e. in selecting the cocaine-paired lever.
• the invention relates to the use of a pharmaceutical composition containing at least one compound of 1-[4-(5-cyanoindol-3- yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and/or one of its biocompatible salts together with at least one solid, liquid or semiiiquid excipient or adjunct for the treatment of substance-related disorders.
• the invention provides a pharmaceutical preparation for the treatment of substance-related disorders characterized in that it contains at least 1-[4- (5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or one of its pharmaceutically acceptable salts.
• the compounds according to the invention are preferably administered in analogy to other known commercially available preparations for the treatment of substance-related disorders (e.g. fluoxetine, fluvoxamine), preferably in doses of between approximately 0.1 and 1000 mg, in particular between 5 and 500 mg per dose unit.
• the composition may be administered once or more times a day for example 2, 3 or 4 times daily or in sustained release form.
• the daily dose is preferably between approximately 0.01 and 100 mg/kg of body weight.
• the specific dose for each patient depends on all sorts of factors, for example on the activity of the specific compound employed, on the age, body weight, general state of health, sex, on the diet, on the time and route of administration, on the excretion rate, pharmaceutical substance combination and severity of the particular disorder to which the therapy relates.
• Oral administration is preferred, but also peroral routes of administration (e.g. intraveneous or transdermal) can be utilized.
• the present invention relates to the use of 1-[4-(5-cyanoindol- 3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof, for the manufacture of a medicament for the treatment of sexual dysfunctions.
• premature ejaculation includes congenital premature ejaculation as well as primary premature ejaculation.
• behavioural measures for sexual function can be used in animal models depending on the targeted dysfunction in humans, e.g. reduced libido, anorgasmia, or ejaculation disorders.
• Measures for sexual activity in animals include fasciiitation or prolongation of penile errection, ejaculatory behaviour or frequency of mating behaviour in male rats, or the percentage of receptive behaviours in female rats [e.g.: S. Ahlenius and K. Larsson, Neurochem. Res., 1997, 22: 1065-1070; S. Ahlenius and K. Larsson, Psychopharmacology, 1998, 137: 374-382; J. Vega-Matuszcyk et al., Pharmacol. Biochem.
• the invention relates furthermore to the use for the manufacture of a medicament for the treatment of sexual dysfunctions in which the pharmacologically acceptable salt is 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2- carbamoyl-benzofuran-5-yl)-piperazine hydrochloride.
• the invention relates to the use of a pharmaceutical composition containing at least one compound of 1-[4-(5-cyanoindol-3- yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and/or one of its biocompatible salts together with at least one solid, liquid or semiliquid excipient or adjunct for the treatment of sexual dysfunctions.
• the invention provides a pharmaceutical preparation for the treatment of sexual dysfunctions characterized in that it contains at least 1-[4-(5- cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or one of its pharmaceutically acceptable salts.
• the compounds according to the invention are preferably administered in analogy to other known commercially available preparations for the treatment of sexual dysfunctions including premature ejaculation (e.g. fluoxetine, fluvoxamine), preferably in doses of between approximately 0.1 and 500 mg, in particular between 5 and 300 mg per dose unit.
• the daily dose is preferably between approximately 5 and 100 mg/kg of body weight for a time period of at least about 3 months, preferably for a time period of at least about 6 months.
• the specific dose for each patient depends on all sorts of factors, for example on the activity of the specific compound employed, on the age, body weight, general state of health, sex, on the diet, on the time and route of administration, on the excretion rate, pharmaceutical substance combination and severity of the particular disorder to which the therapy relates.
• the compounds of the present invention are administered chronically as long as the patient remains sexually active. Oral administration is preferred, but also peroral routes of administration (e.g. intraveneous or transdermal) can be utilized.
• the present invention relates to the use of 1-[4-(5-cyanoindol- 3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof, for the manufacture of a medicament for the treatment of eating disorders and/or obesity and/or anorexia.
• a typical animal model for eating disorders and/or obesity and/or anorexia is named Cumulative Food Intake according to H.C. Jackson, A.M.
• serotonin reuptake inhibitors such as fluoxetine, fluvoxamine, paroxetine or sibutramine (e.g. K. Inoue, N. Kiriike, Y. Fujisaki, M. Kurioka, S. Yamagami, Physiol. Behav. 1997, 61: 603-608; R. Ciccocioppo, I Panocka, C. Polidori, C.T. Dourish, M. Massi Psychopharmacology 1997, 134: 55-63; H.C. Jackson, A.M. Needham, L.J. Hutchins, S.E. Mazurkiewicz, D.J. Heal, Br. J. Pharmacol., 1997, 121: 1758-1762; S.
• fluoxetine e.g. K. Inoue, N. Kiriike, Y. Fujisaki, M. Kurioka, S. Yamagami, Physiol. Behav. 1997, 61: 603-608
• R. Ciccocioppo
• a typical clinical study for anorexia nervosa is described in the following. Twenty ( 20 ) female patients aged 18-40 years suffering from anorexia nervosa as diagnosed by DSM-IV will be treated for an 12 week period with either 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)- piperazine or one of its physiologically acceptable salts or placebo in a double-blind fashion.
• the invention relates furthermore to the use for the manufacture of a medicament for the treatment of eating disorders and/or obesity and/or anrexia in which the pharmacologically acceptable salt is 1-[4-(5- cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride.
• the invention relates to the use of a pharmaceutical composition containing at least one compound of 1-[4-(5-cyanoindol-3- yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and/or one of its biocompatible salts together with at least one solid, liquid or semiiiquid excipient or adjunct for the treatment of eating disorders and/or obesity and/or anorexia.
• the invention provides a pharmaceutical preparation for the treatment of eating disorders and/or obesity and/or anorexia characterized in that it contains at least 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran- 5-yl)-piperazine or one of its pharmaceutically acceptable salts.
• the compounds according to the invention are preferably administered in analogy to other known commercially available preparations for the treatment of eating disorders and/or obesity and/or anrexia (e.g. fluoxetine, fluvoxamine), preferably in doses of between approximately 0.1 and 500 mg, in particular between 5 and 300 mg per dose unit.
• the daily dose is preferably between approximately 0.01 and 10 mg/kg of body weight.
• the specific dose for each patient depends on all sorts of factors, for example on the activity of the specific compound employed, on the age, body weight, general state of health, sex, on the diet, on the time and route of administration, on the excretion rate, pharmaceutical substance combination and severity of the particular disorder to which the therapy relates.
• Oral administration is preferred, but also peroral routes of administration (e.g. intraveneous or transdermal) can be utilized.
• the present invention relates to the use of 1-[4-(5-cyanoindol- 3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof, for the manufacture of a medicament for the treatment of fibromyalgia.
• Fibromyalgia a chronic muscle disorder, is characterized by pain of the whole locomotion system which is not caused by any inflammation or psychological state of the patient combined with chronic fatigue syndrome and multiple tender-points. Further symptoms are disturbance of sleep, morning rigidity, headache, irritable bowel and bladder syndrome, and paresthesias. Patients suffering from fibromyalgia show no increased values of inflammation or increased rheumatoid factors. According to an inquiry in the USA, 2% of the population are affected by fibromyalgia.
• a more sophisticated animal model for fibromyalgia is chronic constrictions of the sciatic nerve in rats associated with hyperalgesia, allodynia and spontaneous pain [G.J. Bennett G.J. and Y.K.Xie, Pain 1988, 33: 87-107].
• rats are anesthesized and 4 ligatures spaced 1 mm apart are loosely tied around the left sciatic nerve. Rats are tested when the chronic state is fully installed, i.e. one week after sciatic nerve surgery, for reactivity to thermal and tactile stimulation.
• a rat is placed in a box.
• thermal stimulation an infrared radiant source is focused under the non-lesioned and lesio ⁇ ed hindpaws and the hindpaw withdrawal latencies are recorded.
• fibromyalgia For tactile stimulation, the tip of an electronic Von Frey probe is applied with increasing pressure on the non-lesioned and lesioned hindpaws, and the force required to induce a paw-withdrawal is recorded.
• a typical clinical study for fibromyalgia is described in the following. Twenty ( 20 ) male or female patients aged 18-65 years suffering from fibromyalgia will be treated with 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2- carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof for eight weeks in an open label clinical study.
• Clinical improvement could be also assessed by means of the number of positive tender points (TP score > 11 from 18) according to the ACR criteria (Arthritis Rheum. 1990, 33: 160-172) for the diagnosis of fibromyalgia.
• the invention relates furthermore to the use for the manufacture of a medicament for the treatment of fibromyalgia in which the pharmacologically acceptable salt is 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2- carbamoyl-benzofuran-5-yl)-piperazine hydrochloride.
• the invention relates to the use of a pharmaceutical composition containing at least one compound of 1-[4-(5-cyanoindol-3- yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and/or one of its biocompatible salts together with at least one solid, liquid or semiliquid excipient or adjunct for the treatment of fibromyalgia.
• the invention provides a pharmaceutical preparation for the treatment of fibromyalgia characterized in that it contains at least 1-[4-(5-cyanoindol- 3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or one of its pharmaceutically acceptable salts.
• the compounds according to the invention are preferably administered in analogy to other known commercially available preparations for the treatment of fibromyalgia (e.g. amitryptiline), preferably in doses of between approximately 0.1 and 500 mg, in particular between 5 and 300 mg per dose unit.
• the daily dose is preferably between approximately 0.01 and 10 mg/kg of body weight.
• the specific dose for each patient depends on all sorts of factors, for example on the activity of the specific compound employed, on the age, body weight, general state of health, sex, on the diet, on the time and route of administration, on the excretion rate, pharmaceutical substance combination and severity of the particular disorder to which the therapy relates.
• Oral administration is preferred, but also peroral routes of administration (e.g. intraveneous or transdermal) can be utilized.
• All the pharmaceutical preparations used for the treatment of sub-type anxiety disorders, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, anorexia or fibromyalgia can be used as pharmaceuticals in human or veterinary medicine.
• a process for the manufacture of a pharmaceutical preparation used for the treatment of sub-type anxiety disorders, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, anorexia or fibromyalgia is characterised in that 1-[4-(5- cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or one of its pharmaceutically acceptable salts are converted into a suitable dosage form together with at least one solid, liquid or semiliquid excipient or adjunct.
• Suitable excipients are organic or inorganic substances which are suitable for enteral (e.g. oral), parenteral or topical adminstration and which do not react with 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)- piperazine and/or one of its biocompatible salts, for example water, vegetable oils, benzyl alcohols, alkylene glycols, polyethylene glycols, glycerol triacetate, gelatine, carbohydrates such as lactose or starch, magnesium stearate, talc, petroleum jelly.
• Forms which are used for oral administration are, in particular, tablets, pills, sugar-coated tablets, capsules, powders, granules, syrups, liquids or drops
• forms for rectal administration are, in particular suppositories
• forms for parenteral administration are, in particular, solvents, preferably oily or aqueous solutions, furthermore suspensions, emulsions or implants
• forms for topical administration are transdermal plasters, ointments, creams or powders.
• 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)- piperazine and/or one of its pharmaceutically acceptable salts may also be lyophilized and the resulting lyophilisates used for example for the preparation of injectable products.
• the abovementioned preparations can be in sterilized form and/or comprise auxiliaries such as glidants, preservatives, stabilizers and/or wetting agents, emulsifiers, salts for modifying the osmotic pressure, buffer substances, colourings, flavourings and/or other active ingredients, e.g. one or more vitamins.
• Preparations may, if desired, be designed to give slow release of 1-[4-(5- cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a biocompatible salt thereof.
• the examples which follow relate to pharmaceutical products:
• a solution of 100 g of 1-[4-(5-cyanoindol-3-yl)butyl] ⁇ 4-(2-carbamoyl- benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof and 5 g of disodium hydrogen phosphate in 3 I of twice-distilled water is brought to pH 6.5 with 2N hydrochloric acid, filter-sterilized, filled into vials, lyophilized under sterile conditions and sealed in sterile form. Each vial comprises 5 mg of active ingredient.
• a mixture of 20 g of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl- benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof is melted with 100 g of soya lecithin and 1400 g of cocoa butter, and the mixture is poured into moulds and left to cool.
• Each suppository comprises 20 mg of active ingredient.
• a solution is prepared from 1 g of 1-[4-(5-cyanoindol-3-yl)butyl]-4- (2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof, 9.38 g of NaH 2 PO 4 -2H 2 O, 28.48 g of Na 2 HPO 4 -12H 2 O and 0.1 g of benzalkonium chloride in 940 ml of twice-distilled water. The pH is brought to 6.8, and the solution is made up to 1 I and sterilized by irradiation. This solution can be used in the form of eyedrops.
• Example F Sugar-coated tablets
• a mixture is tableted analogously to Example E, and the tablets are subsequently coated in the customary manner with a coating of sucrose, potato starch, talc, tragacanth and colouring.
• Example H Ampoules A solution of 1 kg of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl- benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof in 60 I of twice-distilled water is filter-sterilized, filled into ampoules, lyophilized under sterile conditions and sealed in sterile form. Each ampoule comprises 10 mg of active ingredient.
• Example I Spray for inhalation

Landscapes

• Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Epidemiology (AREA)
• Neurology (AREA)
• Biomedical Technology (AREA)
• Neurosurgery (AREA)
• Reproductive Health (AREA)
• Psychiatry (AREA)
• Endocrinology (AREA)
• Pain & Pain Management (AREA)
• Diabetes (AREA)
• Obesity (AREA)
• Rheumatology (AREA)
• Gynecology & Obstetrics (AREA)
• Hematology (AREA)
• Addiction (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Pregnancy & Childbirth (AREA)
• Hospice & Palliative Care (AREA)
• Nutrition Science (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Physical Education & Sports Medicine (AREA)
• Child & Adolescent Psychology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)

Priority Applications (24)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (2)

Family

ID=8238153

Family Applications (1)

Country Status (31)

Cited By (15)

Families Citing this family (10)

Family Cites Families (13)

• 1999
  • 1999-11-15 TW TW088119882A patent/TW518218B/zh not_active IP Right Cessation
• 2000
  • 2000-05-16 KR KR1020017015141A patent/KR100683367B1/ko not_active Expired - Fee Related
  • 2000-05-16 AT AT04001441T patent/ATE337008T1/de active
  • 2000-05-16 JP JP2000620944A patent/JP4884588B2/ja not_active Expired - Fee Related
  • 2000-05-16 BR BR0010948-7A patent/BR0010948A/pt not_active Application Discontinuation
  • 2000-05-16 IL IL14670700A patent/IL146707A0/xx active IP Right Grant
  • 2000-05-16 PT PT00935031T patent/PT1185272E/pt unknown
  • 2000-05-16 CZ CZ20014226A patent/CZ295623B6/cs not_active IP Right Cessation
  • 2000-05-16 HU HU0201275A patent/HU229059B1/hu not_active IP Right Cessation
  • 2000-05-16 MX MXPA01012172A patent/MXPA01012172A/es active IP Right Grant
  • 2000-05-16 PL PL352373A patent/PL199516B1/pl unknown
  • 2000-05-16 AT AT06017231T patent/ATE438399T1/de active
  • 2000-05-16 EP EP04001441A patent/EP1410800B1/en not_active Expired - Lifetime
  • 2000-05-16 DE DE60042710T patent/DE60042710D1/de not_active Expired - Lifetime
  • 2000-05-16 CN CN200910113677A patent/CN101869565A/zh active Pending
  • 2000-05-16 AT AT00935031T patent/ATE263564T1/de active
  • 2000-05-16 SI SI200030423T patent/SI1185272T1/xx unknown
  • 2000-05-16 UA UA2001128861A patent/UA74337C2/uk unknown
  • 2000-05-16 WO PCT/EP2000/004376 patent/WO2000072832A2/en not_active Ceased
  • 2000-05-16 ES ES04001441T patent/ES2271707T3/es not_active Expired - Lifetime
  • 2000-05-16 DK DK00935031T patent/DK1185272T3/da active
  • 2000-05-16 CA CA2615271A patent/CA2615271C/en not_active Expired - Fee Related
  • 2000-05-16 HK HK03100617.0A patent/HK1048444B/zh not_active IP Right Cessation
  • 2000-05-16 CA CA2694866A patent/CA2694866A1/en not_active Abandoned
  • 2000-05-16 EP EP00935031A patent/EP1185272B1/en not_active Expired - Lifetime
  • 2000-05-16 SI SI200030902T patent/SI1410800T1/sl unknown
  • 2000-05-16 PL PL383406A patent/PL199650B1/pl unknown
  • 2000-05-16 PT PT04001441T patent/PT1410800E/pt unknown
  • 2000-05-16 DK DK04001441T patent/DK1410800T3/da active
  • 2000-05-16 DE DE60009697T patent/DE60009697T2/de not_active Expired - Lifetime
  • 2000-05-16 CA CA002372668A patent/CA2372668C/en not_active Expired - Fee Related
  • 2000-05-16 DE DE60030338T patent/DE60030338T2/de not_active Expired - Lifetime
  • 2000-05-16 CN CNA2005100544177A patent/CN1679577A/zh active Pending
  • 2000-05-16 SK SK1646-2001A patent/SK287851B6/sk not_active IP Right Cessation
  • 2000-05-16 TR TR2001/03361T patent/TR200103361T2/xx unknown
  • 2000-05-16 PT PT06017231T patent/PT1736158E/pt unknown
  • 2000-05-16 ES ES06017231T patent/ES2330774T3/es not_active Expired - Lifetime
  • 2000-05-16 CN CNB008081352A patent/CN1198618C/zh not_active Expired - Fee Related
  • 2000-05-16 ES ES00935031T patent/ES2219342T3/es not_active Expired - Lifetime
  • 2000-05-16 US US09/979,922 patent/US6900212B1/en not_active Expired - Lifetime
  • 2000-05-16 AU AU50663/00A patent/AU771778B2/en not_active Ceased
  • 2000-05-16 DK DK06017231T patent/DK1736158T3/da active
  • 2000-05-16 EP EP06017231A patent/EP1736158B1/en not_active Expired - Lifetime
  • 2000-05-16 RU RU2001133342A patent/RU2237477C2/ru not_active IP Right Cessation
  • 2000-05-16 PL PL383006A patent/PL200490B1/pl unknown
  • 2000-05-25 MY MYPI20002314A patent/MY135627A/en unknown
  • 2000-05-26 AR ARP000102575A patent/AR024112A1/es unknown
• 2001
  • 2001-11-22 IL IL146707A patent/IL146707A/en not_active IP Right Cessation
  • 2001-11-26 NO NO20015746A patent/NO322120B1/no not_active IP Right Cessation
  • 2001-12-20 ZA ZA200110485A patent/ZA200110485B/en unknown
• 2004
  • 2004-11-23 US US10/994,226 patent/US7371756B2/en not_active Expired - Lifetime
• 2006
  • 2006-04-06 NO NO20061562A patent/NO324230B1/no not_active IP Right Cessation
  • 2006-11-02 CY CY20061101575T patent/CY1105750T1/el unknown
• 2007
  • 2007-11-28 US US11/946,149 patent/US7642261B2/en not_active Expired - Fee Related
• 2009
  • 2009-10-14 CY CY20091101063T patent/CY1109472T1/el unknown
  • 2009-11-17 US US12/620,049 patent/US20100063062A1/en not_active Abandoned
• 2011
  • 2011-02-10 JP JP2011027903A patent/JP2011148799A/ja active Pending

Also Published As

Similar Documents

Legal Events